Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]EKAP is a radiolabeled small molecule and positron emission tomography (PET) tracer specifically designed for the in vivo imaging and quantification of kappa opioid receptors (KOR) in the human brain. Developed primarily by researchers at the Yale PET Center, [11C]EKAP acts as a selective KOR agonist. It is utilized in clinical research to investigate the role of the kappa opioid system in various neuropsychiatric and behavioral conditions, including disordered eating behaviors (DEB), post-traumatic stress disorder (PTSD), and borderline personality disorder (BPD). By measuring the binding potential of the tracer, researchers can assess KOR availability and distribution, providing insights into interoceptive awareness, stress regulation, and reward processing deficits associated with these disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]EKAP.